티제이팜

비상장계속사업자

TJPHARM CO.LTD

오성덕

Investment Review Report

Auto-filled from disclosures & public data + AI-drafted analysis. Edit, then export to PDF/DOCX.

Editor

1.Deal Terms

2.Valuation / Exit Assumptions

Exit Scenarios100M KRW

3.Fund Eligibility

Fund mandate eligibility — no data, enter manually

Enter fund mandate requirements and applicability (Y/N) to include a table in the report.

4.Capital Changes

Not in DART — enter capital-raise history manually

Enter capital changes such as founding capital and paid-in increases.

5.Stock Options

Enter manually

Enter stock option grant history.

6.Investment Highlights

AI draft — editable

Click 'Generate AI draft' to populate data-grounded investment highlights.

7.Investment Risks

AI draft — editable

Risks are populated after 'Generate AI draft'.

8.Market Analysis

AI draft — editable

9.Business Analysis

AI draft — editable

10.Conclusion (Investment Opinion)

AI draft — editable

11.P&L Projection

Analyst estimates, manual entry (100M KRW). Generates a trend chart & table.

Enter projected revenue / op. profit / net income (100M KRW) by year to add a trend chart and table.
Preview— the document below is saved as PDF/DOCX

Investment Review Report

티제이팜

Business Reg. No. 1238604017 · CEO 오성덕

I.Investment Overview

Target티제이팜 (1238604017)
Investment
Post-deal stake
ValuationPre — / Post —

II.Investment Highlights

No investment highlights written yet.

III.Investment Risks

No risks written yet.

IV.Company Profile

회사명티제이팜
영문명TJPHARM CO.LTD
대표자오성덕
사업자등록번호1238604017
법인등록번호1351110077804
설립일2005.11.02

V.Financial Summary

Per DART disclosure · in 억/만원 (KRW)

Financial trend (100M KRW)

매출액100M KRW5,983.720216,924.420227,328.320237,856.920248,698.72025
영업이익100M KRW49.8202164.8202250.6202351.6202435.72025
순이익100M KRW24.4202135.8202218.2202325.1202439.32025
Item20252024202320222021
자산총계2,692.1억원2,451.2억원2,473.7억원2,225.8억원1,998.6억원
부채총계2,142.7억원1,938.9억원1,985.8억원1,753.8억원1,563.4억원
자본총계549.4억원512.3억원488억원472억원435.3억원
매출액8,698.7억원7,856.9억원7,328.3억원6,924.4억원5,983.7억원
영업이익35.7억원51.6억원50.6억원64.8억원49.8억원
순이익39.3억원25.1억원18.2억원35.8억원24.4억원

VI.Financial Ratios

FY2025 basis

0.41%

영업이익률

0.45%

순이익률

1.46%

ROA

7.16%

ROE

389.99%

부채비율

20.41%

자기자본비율

VII.Valuation & Exit Plan

Exit valuation
Holding period5y
Enter exit assumptions (investment, stake, exit valuation, period) to see MOIC·IRR.

This report compiles disclosure & public data and AI-drafts some sections as a research aid. It is not investment advice; the user bears final responsibility for facts and investment decisions.

티제이팜 투심보고서 | Alpha Lenz